Repairon Expands into North America to Speed Up Clinical Trials and Product Development
GÖTTINGEN, Germany, Feb. 02, 2026 — The German biotechnology firm Repairon GmbH has announced the creation of its wholly-owned subsidiary, Repairon USA, Inc., to facilitate the broadening of clinical trials and to seek regulatory clearance for its primary product in North America. Incorporated in Delaware, Repairon USA will base its headquarters in Providence, Rhode Island. Frank Ahmann, a biomedical industry leader with extensive cardiovascular expertise, has been appointed to head the subsidiary’s operations.
Repairon’s innovative regenerative therapy for heart failure is currently under assessment in a German Phase 2 clinical trial. A recent interim analysis shared at the 2025 American Heart Association Scientific Sessions demonstrated increased heart wall thickness, enhanced cardiac function, and a better quality of life for patients with advanced Heart Failure (HF). These encouraging results necessitate extending clinical trials to additional European sites and to North America. In the United States, 6.7 million adults live with HF, a figure projected to rise to 11.4 million by 2050. Roughly 10% of these patients are estimated to have advanced HF, which carries a very grim outlook. Subject to FDA authorization, Repairon plans to initiate U.S. clinical trials as a central part of its worldwide development plan.
Lothar Germeroth, Ph.D., CEO of Repairon, stated, “We are thrilled to advance toward realizing the promise of our human engineered heart muscle to markedly enhance patients’ lives and alter the trajectory of advanced HF, a debilitating, chronic, and costly condition. In the U.S., the world’s largest individual HF market, economic strains and increasing patient demands on the healthcare system also create a need for novel treatment options such as ours.” Frank Ahmann, who takes on the role of CEO at Repairon USA, commented, “The United States boasts a premier global network of cardiologists and HF specialists who are eager to engage in Repairon’s clinical studies and regulatory approval pathway. Furthermore, Repairon’s therapy is anticipated to provide a practical and economical alternative to hard-to-get transplants and ventricular assist devices.” Rhode Island, with its strategic position and rapidly expanding life sciences sector, is an ideal location for Repairon USA’s headquarters.
Significant Unmet Medical Need in Advanced Heart Failure: Around 5% of Germany’s population is affected by chronic heart failure of varying severity, making it the country’s third leading cause of death. In the United States, heart failure is the most frequent reason for hospitalization and death among the elderly, impacting over 6 million individuals. When heart failure reaches an advanced stage, patients suffer from weakness and discomfort during any physical exertion and even at rest, sometimes necessitating continuous bed rest. For these critically ill patients, the only current treatment choices are mechanical pump devices or a heart transplant.
About Repairon: Repairon GmbH is a German biotechnology company headquartered in Göttingen that specializes in creating regenerative cell therapies for cardiac care. Founded in 2014 on research conducted by Wolfram-Hubertus Zimmermann, MD, Ph.D., and his team at the University Medical Center Goettingen, the company leverages several tissue engineering technologies with established uses in organ repair and drug discovery. Repairon’s leading therapeutic candidate, a human engineered heart muscle sheet, is now being tested in the BioVAT-HF Phase 2 clinical trial as a biological ventricular support tissue for end-stage heart failure.
CONTACT: Company contact: Dr. Lothar Germeroth Repairon GmbH 37079 Göttingen - Germany Email: l.germeroth@repairon.com US contact: Frank Ahmann Repairon USA Providence, RI Email: f.ahmann@repairon.com
